Welcome to our dedicated page for Journey Medical Corporation news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical Corporation stock.
Journey Medical Corporation (symbol: DERM) is a commercial stage pharmaceutical company dedicated to the development and commercialization of products designed to treat dermatological conditions. With a diverse portfolio that includes eight branded and three authorized generic prescription drugs marketed in the United States, Journey Medical is committed to improving the quality of life for patients with skin conditions.
Among the well-known products in their lineup are Qbrexza, a topical treatment for excessive underarm sweating, Accutane, a potent medication for severe acne, Amzeeq, a foam treatment for acne vulgaris, and Exelderm, an antifungal solution. These products highlight the company's dedication to addressing various dermatological needs.
Recently, Journey Medical secured additional capital to support general corporate purposes, including funding for the potential launch of DFD-29. This demonstrates their strategic effort to expand their product offerings and enhance their market presence.
The company is proactive in maintaining transparent communication with its stakeholders. They have scheduled a conference call on March 21, 2024, to discuss financial results and provide a corporate update. Furthermore, another conference call is set for May 13, 2024.
Looking ahead, an important milestone for Journey Medical is the Prescription Drug User Fee Act (PDUFA) goal date on November 4, 2024. This date is crucial for the approval process of their new drug applications, reflecting the company's ongoing efforts in drug development and commercialization.
For more information, investors and interested parties can contact Jaclyn Jaffe at (781) 652-4500 or via email at ir@jmcderm.com. Media inquiries can be directed to Tony Plohoros at (908) 591-2839 or tplohoros@6degreespr.com.
Journey Medical (DERM) reported Q3 2024 financial results with total revenues of $14.6 million, marking a 4% decrease from Q3 2023. The company received FDA approval for Emrosi™, a treatment for inflammatory lesions of rosacea in adults, with launch expected in late Q1 or early Q2 2025. Q3 2024 showed a net loss of $2.4 million ($0.12 per share), compared to net income of $16.8 million in Q3 2023. Gross margin improved to 63.9% from 57.9% year-over-year. The company ended the quarter with $22.5 million in cash and cash equivalents.
Journey Medical (Nasdaq: DERM) has received FDA approval for Emrosi™, a 40 mg minocycline hydrochloride extended-release capsule for treating inflammatory lesions of rosacea in adults. The approval is backed by successful Phase 3 clinical trials where Emrosi demonstrated superior efficacy compared to both Oracea® 40 mg capsules and placebo. The trials met all co-primary and secondary endpoints with no significant safety concerns. Journey Medical plans to launch Emrosi in the U.S. market through its dermatology-focused sales force, with initial supply expected late Q1 or early Q2 2025.
Journey Medical (Nasdaq: DERM) presented data on DFD-29, a minocycline-based treatment for rosacea, at the 44th Fall Clinical Dermatology Conference. The study compared DFD-29 (40mg) with doxycycline (40mg) over 21 days, showing DFD-29 achieved higher dermal concentrations from Day 1. The company's New Drug Application is under FDA review with a PDUFA date of November 4, 2024. The randomized study demonstrated that DFD-29's modified-release formulation maintained consistent plasma levels while providing superior skin penetration compared to doxycycline, with both treatments showing good tolerability.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved prescription drugs for dermatological conditions, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is set to take place on Wednesday, October 9, 2024, in New York City.
Members of Journey Medical's management team will be attending one-on-one meetings during the conference. This participation highlights the company's commitment to engaging with investors and industry professionals in the healthcare sector.
The conference provides an opportunity for Journey Medical to showcase its focus on selling and marketing dermatological treatments, potentially attracting investor interest and fostering business relationships within the pharmaceutical industry.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, has announced its participation in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference. The event is set to take place on Thursday, September 12, 2024 in New York City.
Claude Maraoui, President and CEO of Journey Medical, will be attending the conference to engage in one-on-one meetings with investors and industry professionals. This participation underscores the company's commitment to growth and investor relations in the pharmaceutical sector, particularly in the field of dermatology.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Claude Maraoui, President and CEO, will present a corporate overview available for on-demand viewing starting September 9, 2024, at 7:00 a.m. ET.
The company will also engage in one-on-one meetings during the conference. Investors can access a replay of the presentation on Journey Medical's website for approximately 30 days after the event, providing an opportunity to gain insights into the company's strategies and performance in the dermatological pharmaceutical market.
Journey Medical (Nasdaq: DERM) reported financial results for Q2 2024. Key highlights include:
- Total revenues of $14.9 million, a 14% increase from Q1 2024
- Net loss reduced by $5.0 million to $3.4 million or $(0.17) per share
- Positive Adjusted EBITDA of $0.3 million
- Cash and cash equivalents of $23.9 million as of June 30, 2024
The company's New Drug Application for DFD-29 to treat rosacea is under FDA review with a PDUFA goal date of November 4, 2024. Journey Medical appointed Joseph M. Benesch as CFO and Michael C. Pearce to its Board of Directors. The company remains on track to deliver its 2024 financial guidance.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focusing on FDA-approved dermatological treatments, has announced it will release its second quarter 2024 financial results on August 12, 2024, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Interested parties can join the call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). Participants can also register online to receive a dial-in number. A live audio webcast will be available on the company's website and will remain accessible for approximately 30 days after the call.
Journey Medical (Nasdaq: DERM) has appointed Michael C. Pearce to its Board of Directors, effective July 9, 2024. Pearce, an experienced principal investor and advisor in the healthcare sector, has an extensive background, including roles at EP Group, Evening Post Industries (EPI), and as Chairman of Range Therapeutics. His appointment comes as Journey Medical approaches the potential FDA approval of DFD-29, a promising treatment for rosacea, in November 2024. Pearce's strategic, business, and financial expertise is expected to bring significant value to Journey Medical's leadership as it continues to pursue its corporate goals.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, announces its participation in the Alliance Global Partners’ Virtual Healthcare Company Showcase.
CEO Claude Maraoui will participate in a fireside chat on May 21, 2024, at 1:00 p.m. ET. The event will provide insights into the company's operations and future plans.
Registration for the conference is available online, and a replay of the chat will be accessible on Journey Medical’s website for 30 days after the event.
FAQ
What is the current stock price of Journey Medical Corporation (DERM)?
What is the market cap of Journey Medical Corporation (DERM)?
What does Journey Medical Corporation do?
What are some of Journey Medical's key products?
What recent achievements has Journey Medical Corporation made?
When is the next conference call for Journey Medical?
What is the PDUFA goal date for Journey Medical?
How can I contact Journey Medical for investor relations?
Who handles media relations for Journey Medical?
What is DFD-29?
Where are Journey Medical's products marketed?
What is the focus of Journey Medical Corporation?
